社区急性过敏反应中肾上腺素使用与急救系统启动推荐:国际共识报告
该国际共识由34名专家组成的小组于2024年1月至2025年5月制定,针对社区急性过敏反应中肾上腺素给药和急救系统启动的临床决策。通过改良德尔菲法,专家组开发了24个临床场景、9个候选修饰因素和12条候选急救系统启动推荐,第一阶段21条声明达成推荐使用肾上腺素的共识,2条达成不推荐共识,1条未达成共识,5个修饰因素和10条急救系统启动推荐达成共识;第二阶段在15个临床场景中2个达成推荐使用肾上腺素的共识。该共识旨在整合入技术决策支持工具以优化反应管理。
要点
- 专家组开发了24个反映不同严重程度的临床场景,第一阶段21条声明达成推荐使用肾上腺素的共识,2条达成不推荐共识,1条未达成共识。
- 9个候选修饰因素中5个达成共识,包括可能降低肾上腺素给药阈值的因素(如哮喘病史)。
- 12条候选急救系统启动推荐中10条达成共识。
- 第二阶段在15个未推荐或未达成共识使用肾上腺素的临床场景中测试修饰因素,2个场景达成推荐使用肾上腺素的共识。
- 共识推荐可整合入技术决策支持工具,以改善反应管理、患者结局和医疗资源利用。
适用人群与场景
- 社区环境中发生急性过敏反应的患者。
处置流程与药物剂量
- 专家组达成共识推荐在特定临床场景中使用肾上腺素(肾上腺素)治疗急性过敏反应,具体场景见原文24个临床场景。
- 专家组达成共识推荐在特定临床场景中启动急救医疗服务(EMS),共10条共识推荐。
- 5个共识修饰因素可能降低肾上腺素给药阈值,包括哮喘病史(示例)。
研究设计与关键结果
- 研究为国际共识制定项目,34名专家参与,时间范围为2024年1月至2025年5月。
- 第一阶段:24个临床场景中21条声明达成推荐使用肾上腺素的共识,2条达成不推荐共识,1条未达成共识;9个候选修饰因素中5个达成共识;12条候选EMS启动推荐中10条达成共识。
- 第二阶段:在15个未推荐或未达成共识使用肾上腺素的临床场景中测试共识修饰因素,2个场景达成推荐使用肾上腺素的共识。
证据类型、等级与局限
- 证据类型:国际共识报告,采用改良德尔菲法。
- 局限:原文未报告局限性。
对床旁实践的改变
- 共识推荐可整合入技术决策支持工具,以增强反应管理、改善患者结局、优化医疗资源利用并提升患者和照护者自我效能。
指南或共识出处
- 国际共识报告,发表于J Allergy Clin Immunol。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Limited research exists on when to administer epinephrine (adrenaline) or activate emergency medical services (EMS) during acute allergic reactions in community settings. This contributes to suboptimal patient care, including both the underuse and overuse of epinephrine, as well as potentially unnecessary emergency department visits.
OBJECTIVE: We developed consensus recommendations for administering epinephrine and activating EMS during acute allergic reactions.
METHODS: From January 2024 to May 2025, we assembled a 34-member international panel of experts to develop clinical scenarios reflecting varying severity levels within and across organ systems, candidate modifiers that may lower the threshold for epinephrine administration (eg, history of asthma), and candidate EMS activation recommendations. In phase 1, the panel engaged in a modified Delphi process to reach consensus on these outputs. In phase 2, we tested each consensus modifier by embedding it into scenarios where epinephrine was not recommended or lacked consensus, to assess potential impacts on treatment decisions.
RESULTS: The expert panel developed 24 clinical scenarios, 9 candidate modifiers, and 12 candidate EMS activation recommendations. During the first phase, 21 statements reached consensus to recommend epinephrine, 2 reached consensus not to recommend it, and 1 did not reach a consensus. There were 5 consensus modifiers and 10 consensus EMS activation recommendations. In the second phase, 2 of the 15 clinical scenarios reached consensus to recommend epinephrine administration.
CONCLUSION: We developed consensus recommendations for administering epinephrine and activating EMS during acute allergic reactions in community settings. Integrating them into technology-based decision support tools may enhance reaction management, improve patient outcomes, optimize health care utilization, and empower patient and caregiver self-efficacy.
参考来源
- Dribin TE, Sampson HA, Anagnostou A, et al. Epinephrine and emergency medical services activation recommendations during acute allergic reactions in community settings: International consensus report. J Allergy Clin Immunol. 2025. PMID: 41386477. doi:10.1016/j.jaci.2025.11.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。